Acadia Pharmaceuticals (ACAD) Receivables - Other (2013 - 2026)

Acadia Pharmaceuticals' Receivables - Other history runs 14 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 63.52% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 63.52% increase from a year earlier, with the FY2025 full-year figure at $26.8 million, up 349.53% from the prior year.
• Receivables - Other fell to $13.0 million in Q1 2026 per ACAD's latest filing, from $26.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $26.8 million in Q4 2025 and bottomed at $403000.0 in Q3 2022.
• The 5-year median for Receivables - Other is $5.4 million (2024), against an average of $7.6 million.
• Across the five-year window, Receivables - Other slumped 58.54% in 2022 and jumped 602.54% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $885000.0 in 2022, then surged by 361.36% to $4.1 million in 2023, then surged by 45.87% to $6.0 million in 2024, then jumped by 349.53% to $26.8 million in 2025, then sank by 51.32% to $13.0 million in 2026.
• Per Business Quant, the three latest ACAD Receivables - Other figures stand at $13.0 million (Q1 2026), $26.8 million (Q4 2025), and $23.6 million (Q3 2025).